ADA Scientific Sessions 2026 Abstract
Novel Oral Brain Penetrant NLRP3 Inhibitor PSTC2501 for Treatment of Obesity and Cardiovascular Diseases
Experiments in animalsInterventions
Papers by Zhenzhen Zhu
3 results
- ADA Scientific Sessions 2026 Abstract
First Disclosure of PSTC1411, a Novel Oral G-Protein-Biased Apelin Agonist Demonstrating Monotherapy Efficacy for Weight Loss and Muscle Preservation
Experiments in animalsInterventions - ADA Scientific Sessions 2025 Abstract
Novel Oral Apelin Receptor Agonist PSTC1201 for Selective Weight Loss with Muscle Preservation When Combined with Semaglutide in DIO Mice Model
Experiments in animalsInterventions